Stock Market Reviews

OBIO (Orchestra BioMed Holdings, Inc.) News

Get the latest news, insights, and market updates on OBIO (Orchestra BioMed Holdings, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Orchestra BioMed Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates
  Secured $147.6 million in proceeds and committed capital following completion of strategic transactions and concurrent public and private equity offerings, led by $71.6 million in committed capital from Medtronic and Ligand, as well as $30 million from TerumoInitiated patient enrollments in the Virtue Trial evaluating Virtue® Sirolimus AngioInfusion™ Balloon (“Virtue SAB”) trial versus commercially available paclitaxel-coated balloon Demonstrated partnership-driven business model execution with
  Nov 10, 2025 - $OBIO
• Orchestra BioMed Holdings, Inc. (OBIO) Reports Q3 Loss, Beats Revenue Estimates
  Orchestra BioMed Holdings, Inc. (OBIO) delivered earnings and revenue surprises of -5.26% and +15.42%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
  Nov 10, 2025 - $OBIO
• Orchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
  Orchestra BioMed Holdings, Inc. (OBIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
  Nov 4, 2025 - $OBIO
• Orchestra BioMed to Host Business Update Call on November 12, 2025
  NEW HOPE, Pa., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, today announced that company management will host a business update call on Wednesday, November 12th at 8:00 AM ET. The business update will focus on recent significant clinical, strategic and financing develop
  Nov 3, 2025 - $OBIO
• The past five years for Orchestra BioMed Holdings (NASDAQ:OBIO) investors has not been profitable
  It is a pleasure to report that the Orchestra BioMed Holdings, Inc. ( NASDAQ:OBIO ) is up 60% in the last quarter. But...
  Nov 1, 2025 - $OBIO
• Canadian-Made Technology Gives Hospital Teams Clearer Images at the Bedside
  TORONTO, October 30, 2025--Each year, more than 20 million diagnostic X-ray procedures are performed in Canada according to Health Canada. While regular X-rays are used every day in hospitals, they sometimes miss important details – depending on the case and imaging conditions. That’s because bones and other body parts can overlap in the images.
  Oct 30, 2025 - $OBIO
• Orchestra BioMed and Terumo Enter into New $30 Million Virtue SAB Strategic Agreements
  New agreement grants Terumo Virtue SAB coronary indication right of first refusal and supersedes prior distribution agreementTerumo to pay a total of $30 million to Orchestra BioMedOrchestra BioMed retains all development and distribution rights to Virtue SAB in all indicationsOrchestra BioMed recently initiated patient enrollment for the Virtue Trial, its U.S. pivotal IDE trial of Virtue SAB in the treatment of coronary in-stent restenosis (“ISR”) NEW HOPE, Pa., Oct. 28, 2025 (GLOBE NEWSWIRE) -
  Oct 28, 2025 - $OBIO
• Orchestra BioMed Announces First Patients Enrolled in Virtue® SAB US Pivotal IDE Coronary Trial
  Orchestra BioMed’s Virtue® Sirolimus AngioInfusionTM Balloon (“Virtue SAB”) is the first non-coated drug-eluting balloon system designed to deliver a large liquid dose of proprietary extended-release sirolimus (“SirolimusEFRTM”)The Virtue Trial is the first U.S. investigational device exemption (“IDE”) head-to-head randomized coronary pivotal trial evaluating a sirolimus-eluting balloon versus a commercially available paclitaxel-coated balloon (AGENT™) Coronary in-stent restenosis (“ISR”), the c
  Oct 27, 2025 - $OBIO
• Fixing fragmentation: Life Sciences Central launches to strengthen Canada's commercialization engine
  Ontario's life sciences sector is taking a major leap forward with the launch of Life Sciences Central, a new collaborative initiative that brings together the commercialization services, investment networks and talent resources of three of the province's leading innovation organizations: MaRS Discovery District (MaRS), OBIO® and Toronto Innovation Acceleration Partners (TIAP).
  Oct 27, 2025 - $OBIO
• OBIO® Introduces the Future Female Leaders in Life Sciences
  TORONTO, October 23, 2025--OBIO® is pleased to announce the women-led companies selected for the third cohort of its Women in Health Initiative (WiHI) Seed Program. Now in its third cohort, the WiHI Seed Program was established in 2023 to address the significant barriers that women-led companies face in accessing financing and wraparound supports.
  Oct 23, 2025 - $OBIO